[ad_1]
Press release
Hørsholm, Denmark and Cambridge, Mbadachusetts, USA, July 21, 2019 – Oncology Venture A / S announces today that the investor warrants will be traded on Nasdaq First North effective July 24, 2019, under the short name OV TO 1 and ISIN code DK0061139581.
One (1) investor mandate received on the OV Rights Offering this spring entitles the holder to subscribe for one (1) new share in Oncology Venture A / S at an issue price of SEK 7.50.
Investor mandates may be executed in subsequent periods;
September 1, 2019 – September 6, 2019
December 1, 2019 – December 6, 2019
April 1, 2020 – April 10, 2020
May 1, 2020 – May 31, 2020
For more information, please contact:
For investor inquiries
Ulla Hald Buhl, Director of Operations
IR and communications
E-mail: [email protected]
Phone +45 21 70 10 49
For media inquiries
Thomas Pedersen
Carrotize PR & Communications
E-mail: [email protected]
Phone +45 60 62 93 90
About Oncology Venture A / S
Oncology Venture A / S is engaged in the research and development of anti-cancer drugs through its 100% subsidiary, Oncology Venture Product Development ApS. Oncology Venture Uses Drug Response Prediction (DRP)® -Increase significantly the probability of success of clinical trials. DRP® has proven its ability to provide a statistically significant prediction of the clinical outcome of drug therapy in cancer patients in 29 of the 37 clinical studies reviewed and is currently showing promising results in an ongoing Phase 2 study undergoing prospective use of LiPlaCis and its rescue treatment® monitor, match and treat patients with metastatic bad cancer. The DRP® Changed the odds compared to traditional pharmaceutical development. Instead of treating all patients with a particular type of cancer, the tumor genes of the patients are first examined and only the patients most likely to respond to the treatment will be treated. With a better defined group of patients, risks and costs are reduced while the development process becomes more efficient.
The current OV product portfolio includes: LiPlaCis®, a liposomal formulation of cisplatin in an ongoing phase 2 trial on bad and prostate cancer; 2X-121, an inhibitor of PARP in an ongoing phase 2 bad cancer and ovarian cancer; dovitinib, for which DRP has been proven in five indications. The regulatory strategy for dovitinib is to submit a new drug application to the FDA for marketing approval for dovitinib and its DRP based on existing Novartis kidney cancer data. 2X-111, a liposomal formulation of doxorubicin being manufactured for phase 2 bad cancer; irofulven, a phase 2 is underway for prostate cancer; and APO010, a Phase 1/2 immuno-oncology product for multiple myeloma.
Oncology Venture created two companies under the name Special Purpose Vehicles: Oncology Venture US Inc. (formerly 2X Oncology Inc.), a US-based specialty medicine company focused on the development of 2X-121 and 2X-111, and OV-SPV 2, a Danish company that will test and develop dovitinib. Oncology Venture A / S holds an 84% stake in Oncology Venture US and 63% of dovitinib, with the requirement to purchase an additional 12% and the opportunity to acquire the final 25%.
Learn more about oncologyventure.com
Follow us on social networks:
Facebook: https://www.facebook.com/oncologyventure/
LinkedIn: https://www.linkedin.com/company/oncology-venture/
Twitter: https://twitter.com/OncologyVenture
Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are beyond the control of OV, and which could cause actual results to differ materially from those discussed in the forward-looking statements. Forward-looking statements include statements regarding plans, objectives, objectives, future events, performance and / or other OV information that is not historical information. All of these forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements that may accompany the forward-looking statements. OV badumes no obligation to publicly update or revise forward-looking statements to reflect events or circumstances subsequent to the date indicated, except as required by law.
Certified Advisor: Svensk Kapitalmarknadsgranskning AB, Email: [email protected], Phone: +46 11 32 30 732
-
Oncology Venture publication of the date of negotiation of the mandates of investor
[ad_2]
Source link
